Physician profile
Patrick Delsanto
NPI 1275983017
$3,835.74
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $199 · 2021: $1,467 · 2022: $311 · 2023: $667 · 2024: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,222.91 | 2021 | |
| Abbvie INC. | $452.12 | 2021-2024 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $384.83 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.74 | 2023-2024 | Jardiance |
| Pfizer INC. | $248.12 | 2019-2024 | |
| Glaxosmithkline, LLC. | $193.53 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $192.13 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $133.64 | 2020-2024 | Airsupra, Farxiga |
| Amgen INC. | $129.14 | 2019-2024 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $106.86 | 2019 | |
| Exact Sciences Corporation | $96.89 | 2023-2024 | Cologuard Collection Kit |
| Viiv Healthcare Company | $96.29 | 2023-2024 | Apretude |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.12 | 2022 | |
| Gilead Sciences, INC. | $64.41 | 2023 | |
| Abbott Laboratories | $50.06 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.93 | 2020-2021 | |
| Almatica Pharma LLC | $19.79 | 2023 | Gralise |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Nevro Corp. | $18.41 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $17.65 | 2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $15.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Delsanto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.